Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 11, 2012, Pages 1387-1408

  Leone Roberti Maggiore, Umberto ^a   Salvatore, Stefano ^b   Alessandri, Franco ^a   Remorgida, Valentino ^a   Origoni, Massimo ^b   Candiani, Massimo ^b   Venturini, Pier Luigi ^a   Ferrero, Simone ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Adverse events; Antimuscarinics; Overactive bladder; Pharmacokinetics; Tolerability

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DARIFENACIN; FESOTERODINE; IMIDAFENACIN; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

AREA UNDER THE CURVE; BINDING AFFINITY; BLURRED VISION; CONSTIPATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FIRST PASS EFFECT; GENETIC POLYMORPHISM; HUMAN; MAXIMUM PLASMA CONCENTRATION; OVERACTIVE BLADDER; PERSONALIZED MEDICINE; REVIEW; SINGLE DRUG DOSE; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; BENZILATES; BENZOFURANS; CHRONIC DISEASE; CRESOLS; DRUG COMBINATIONS; FEMALE; HUMANS; IMIDAZOLES; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; NOCTURIA; PHENYLPROPANOLAMINE; PYRROLIDINES; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 84867522798     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.714365     Document Type: Review

References (174)

1. Haylen BT, De Ridder D, Freeman RM, et al. International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4-20
2. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006;50:1306-14
3. Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;108:1132-8
4. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: Results from the EPIC study. BJU Int 2008;101:1388-95
5. Cardozo L. Systematic review of overactive bladder therapy in females. Can Urol Assoc J 2011;5:139-42
6. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279-90
7. Mukerji G, Yiangou Y, Grogono J, et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 2006;176:367-73
8. Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology 2009;83:259-69
9. Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci 1999;64:419-28
10. Uchiyama T, Chess-Williams R. Muscarinic receptor subtypes of the bladder and gastrointestinal tract. J Smooth Muscle Res 2004;40:237-47
11. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006
12. Andersson KE. Antimuscarinic mechanisms and the overactive detrusor: An update. Eur Urol 2011;59:377-86
13. Yusup A, Akino H, Miwa Y, et al. Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder. Eur J Pharmacol 2007;577:143-9
14. Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: A UK experience. BJU Int 2012;doi: 10.1111/j.1464-410X.2012.11023.x
15. Shaya FT, Blume S, Gu A, et al. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005;11:121-9
16. Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: A systematic review of the literature. Int J Clin Pract 2011;65:567-85
17. Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: A randomized, double-blind, placebo controlled, multicenter study. J Urol 2009;181:1764-72
18. Baldwin CM, Keating GM. Transdermal oxybutynin. Drugs 2009;69:327-37
19. Alabaster VA. Discovery & development of selective M3 antagonists for clinical use. Life Sci 1997;60:1053-60
20. Beaumont KC, Cussans NJ, Nichols DJ, Smith DA. Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man. Xenobiotica 1998;28:63-75
21. Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet 2006;45:325-50
22. Fuhr U, Staib AH, Harder S, et al. Absorption of ipsapirone along the human gastrointestinal tract. Br J Clin Pharmacol 1994;38:83-6
23. Kerbusch T, Wählby U, Milligan PA, Karlsson MO. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol 2003;56:639-52
24. Malhotra BK, Wood N, Sachse R. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther 2009;47:570-8
25. Zinner N. Darifenacin: A muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. Expert Opin Pharmacother 2007;8:511-23
26. Michel MC. Fesoterodine: A novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008;9:1787-96
27. Malhotra B, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008;46:556-63
28. Ney P, Pandita RK, Newgreen DT, et al. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int 2008;101:1036-42
29. Simon HU, Malhotra B. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Swiss Med Wkly 2009;139:146-51
30. McKeage K, Keating GM. Fesoterodine. Drugs 2009;69:731-8
31. Nilvebrant L, Hallen B, Larsson G. Tolterodine-a new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data. Life Sci 1997;60:1129-36
32. Malhotra BK, Glue P, Sweeney K, et al. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007;81:377-85
33. Malhotra B, Wood N, Guan Z, et al. Pharmacokinetic profile of fesoterodine, a novel antimuscarinic treatment for overactive bladder. Br J Clin Pharmacol 2008;65:999-1000
34. Malhotra B, Gandelman K, Sachse R, et al. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 2009;16:4481-9
35. Malhotra B, Dickins M, Alvey C, et al. Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol 2011;72:263-9
36. Kanayama N, Kanari C, Masuda Y, et al. Drug-drug interactions in the metabolism of imidafenacin: Role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. Xenobiotica 2007;37:139-54
37. Kobayashi F, Yageta Y, Segawa M, Matsuzawa S. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung 2007;57:92-100
38. Murakami S, Yoshida M, Iwashita H, et al. Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urol Int 2003;71:290-8
39. Ohno T, Nakade S, Nakayama K, et al. Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Br J Clin Pharmacol 2008;65:197-202
40. Shimada H, Yafune A, Shibata H, et al. Phase I clinical study of imidafenacin (KRP-197/ONO-8025): single-dose safety and pharmacokinetics of imidafenacin in healthy subjects. J Clin Ther Med 2007;23:233-48
41. Shimada H, Hasunuma T, Hirahara Y, Ishikawa N. Pharmacokinetic study of imidafenacin (KRP-197/ONO-8025): Pharmacokinetics of single oral administration of imidafenacin tablet 0.1 mg and food-effect on its oral absorption in healthy male volunteers. J Clin Ther Med 2007;23:273-85
42. Ohmori S, Miura M, Toriumi C, et al. Absorption, metabolism and excretion of [14C] imidafenacin, a new compound for treatment of overactive bladder, following oral administration to healthy male subjects. Drug Metab Dispos 2007;35:1624-33
43. Shimada H, Shibata H, Hirahara Y, Masuda Y. Investigation on safety and pharmacokinetic profile of imidafenacin (KRP-197/ONO-8025) after single administration in the eldery. J Clin Ther Med 2007;23:263-72
44. Ohno T, Nakayama K, Nakade S, et al. Effect of itraconazole on the pharmacokinetics of imidafenacin in healthy subjects. J Clin Pharmacol 2008;48:330-4
45. Nakade S, Ohno T, Nakayama K, et al. No effect of imidafenacin, a novel antimuscarinic drug, on digoxin pharmacokinetics in healthy subjects. Drug Metab Pharmacokinet 2008;23:95-100
46. Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-62
47. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N- desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997;157:1093-7
48. Sathyan G, Chancellor MB, Gupta SK. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 2001;52:409-17
49. Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988;35:515-20
50. Caldwell J, Marsh MV. Metabolism of drugs by the gastrointestinal tracts. In: George CF, Shand DG, editors. Clinical pharmacology and therapeutics 1: Presystemic drug elimination. Butterworth Scientific-; London: 1982. p. 29-42
51. Paine MF, Khaighi M, Fisher JM, et al. Characterization of interintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997;283:1552-62
52. Hughes KM, Lang JCT, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992;22:859-69
53. Alberti I, Grenier A, Kraus H, Carrara DN. Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. Expert Opin Drug Deliv 2005;2:935-50
54. Comer AM, Goa KL. Extended-release oxybutynin. Drugs Aging 2000;16:149-55
55. Davila GW. Transdermal oxybutynin: A new treatment for overactive bladder. Expert Opin Pharmacother 2003;4:2315-24
56. Staskin DR, Robinson D. Oxybutynin chloride topical gel: A new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother 2009;10:3103-11
57. Lukkari E, Hakonen T, Neuvonen PJ. The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids. Eur J Clin Pharmacol 1998;53:351-4
58. Hughes KM, Lang JC, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992;22:859-69
59. Uchida S, Kurosawa S, Fujino Oki T, et al. Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain. Life Sci 2007;80:2454-60
60. Wuest M, Weiss A, Waelbroeck M, et al. Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedebergs Arch Pharmacol 2006;374:87-97
61. Hüller G, Haustein KO, Scheithauer S. Studies on the metabolic pattern of propiverine in urine after single administration. Pharmazie 1988;43:91-5
62. Sugiyama Y, Yoshida M, Masunaga K, et al. Pharmacological effects of propiverine and its active metabolite, M-1, on isolated human urinary bladder smooth muscle, and on bladder contraction in rats. Int J Urol 2008;15:76-81
63. Yamada S, Ito Y, Taki Y, et al. The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics. Drug Metab Dispos 2010;38:1314-21
64. Müller C, Siegmund W, Huupponen R, et al. Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine. Eur J Drug Metab Pharmacokinet 1993;18:265-72
65. Siegmund W, Sille'n U, Läckgren G, et al. Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder. Clin Pharmacokinet 2010;49:335-42
66. May K, Giessmann T, Wegner D, et al. Oral absorption of propiverine solution and of the immediate and extended release dosage forms: Influence of regioselective intestinal elimination. Eur J Clin Pharmacol 2008;64:1085-92
67. Meisel P, Langner S, Siegmund W. In-vitro binding of propiverine hydrochloride and some of its metabolites to serum albumin in man. J Pharm Pharmacol 1997;49:270-2
68. Haustein KO, Hüller G. On the pharmacokinetics and metabolism of propiverine in man. Eur J Drug Metab Pharmacokinet 1988;13:81-90
69. Siepmann M, Nokhodian A, Thümmler D, Kirch W. Pharmacokinetics and safety of propiverine in patients with fatty liver disease. Eur J Clin Pharmacol 1998;54:767-71
70. Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, et al. Effect of propiverine on cytochrome P450 enzymes: A cocktail interaction study in healthy volunteers. Drug Metab Dispos 2005;33:1859-66
71. Siegmund W, Siegert J, Richter K, et al. Influence of a Fat-Rich Meal on Bioavailability of Extended-Release and Immediate-Release Propiverine. J Clin Pharmacol 2012;52:681-90
72. Kuipers ME, Krauwinkel WJ, Mulder H, Visser N. Solifenacin demonstrates high absolute bioavailability in healthy men. Drugs R D 2004;5:73-81
73. Doroshyenko O, Fuhr U. Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet 2009;48:281-302
74. Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother 2001;2:1685-701
75. Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterodine-a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997;327:195-207
76. Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmcother 2000;11:13-27
77. Postlind H, Danielson A, Lindgren A, Andersson SH. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998;26:289-93
78. Brynne N, Stahl MM, Halle'n B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: A new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997;35:287-95
79. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229-43
80. Alva'n G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7
81. Ozawa S, Soyama A, Saeki M, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 2004;19:83-95
82. Brynne N, Dale'n P, Alva'n G, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 1998;63:529-39
83. Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 2001;40:227-35
84. Clemett D, Jarvis B. Tolterodine: A review of its use in the treatment of overactive bladder. Drugs Aging 2001;18:277-304
85. Olsson B, Brynne N, Johansson C, Arnberg H. Food increases the bioavailability of tolterodine but not effective exposure. J Clin Pharmacol 2001;41:298-304
86. Schwantes U, Topfmeier P. Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexiachances for improvement of therapy. Int J Clin Pharmacol Ther 1999; 37:209-18
87. Madersbacher H, Rovner E. Trospium chloride: The European Experience Expert Opin Pharmacother. 2006;7(10):1373-80, Indevus Pharmaceuticals, Inc., Sanctura- (trospium chloride) prescribing information. Indevus Pharmaceuticals, Inc; Lexington, MA: 2004
88. Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004;64:2433-46
89. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes. Pharmacol Toxicol 1999;85:299-304
90. Diefenbach K, Donath F, Maurer A, et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig 2003;23:395-404
91. Madersbacher H, Rovner E. Trospium chloride: The European experience. Expert Opin Pharmacother 2006;7:1373-80
92. Oefelein MG. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 2011;34:733-54
93. MacDiarmid SA. Maximizing anticholinergic therapy for overactive bladder: Has the ceiling been reached? BJU Int 2007;99:8-12
94. Schneider T, Marschall-Kehrel D, Hanisch JU, Michel MC. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients? Int J Clin Pract 2010;64:1287-93
95. Krauwinkel WJ, Smulders RA, Mulder H, et al. Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther 2005;43:227-38
96. Michel MC, Schneider T, Krege S, Goepel M. Does gender or age affect the efficacy and safety of tolterodine? J Urol 2002;168:1027-31
97. Dmochowski R, Abrams P, Marschall-Kehrel D, et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 2007;51:1054-64
98. Herschorn S, Stothers L, Carlson K, et al. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: Results of the VECTOR trial. J Urol 2010;183:1892-8
99. Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005;23:248-52
100. Dmochowski RR, Davila GW, Zinner NR, et al. For The Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168:580-6
101. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: A multicentre, community-based, randomized study. BJU Int 2007;99:836-44
102. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: A randomized controlled trial. JAMA 1998;280:1995-2000
103. Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 2000;95:718-21
104. MacDiarmid SA, Anderson RU, Armstrong RB, Dmochowski RR. Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: An analysis of data from 3 flexible dosing studies. J Urol 2005;174:1301-5
105. Anderson RU, MacDiarmid S, Kell S, et al. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2006;17:502-11
106. Dmochowski RR, Nitti V, Staskin D, Luber K. Transdermal oxybutynin in the treatment of adults with overactive bladder: Combined results of two randomized clinical trials. World J Urol 2005;23:263-70
107. Gotoh M, Yokoyama O, Nishizawa O, et al. Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. Int J Urol 2011;18:365-73
108. Abrams P, Cardozo L, Chapple C, et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2006;13:692-8
109. Zinner NR, Dmochowski RR, Staskin DR, et al. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn 2011;30:1214-19
110. Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: Results from a placebo-controlled interventional study. Urology 2008;71:449-54
111. Rackley R, Weiss JP, Rovner ES, et al. 037 STUDY GROUP. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006;67:731-6
112. Herschorn S, Heesakkers J, Castro-Diaz D, et al. Disease Management Study Team. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms. Curr Med Res Opin 2008;24:3513-21
113. Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008;71:839-43
114. Vella M, Cardozo L. Review of fesoterodine. Expert Opin Drug Saf 2011;10:805-8
115. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12
116. Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007;178:2488-94
117. Homma Y, Yamaguchi T, Yamaguchi O. A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2008;15(9):809-15
118. Homma Y, Yamaguchi O. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2008;15:986-91
119. Homma Y, Yamaguchi O. Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2009;16:499-506
120. Zaitsu M, Mikami K, Ishida N. Takeuchi T. comparative evaluation of the safety and efficacy of long-term use of imidafenacin and solifenacin in patients with overactive bladder: A prospective, open, randomized, parallel-group Trial (the LIST Study). Adv Urol 2011;2011:854697
121. Vesicare- (Solifenacin succinate). Full prescribing information. Yamanouchi Pharma America, Inc. And GlaxoSmithKline; Norman, Ok, USA: 2004
122. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-24
123. Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005;95:580-6
124. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45:420-9
125. Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;CD003781
126. Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012;1:CD005429
127. Harrington AM, Peck CJ, Liu L, et al. Localization of muscarinic receptors M1R, M2R and M3R in the human colon. Neurogastroenterol Motil 2010;22:999-1008
128. Meek PD, Evang SD, Tadrous M, et al. Overactive bladder drugs and constipation: A meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci 2011;56:7-18
129. Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: Pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005;48:471-7
130. Kaplan SA, Schneider T, Foote JE, et al. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: A prospective, head-to-head, placebo-controlled trial. BJU Int 2011;107:1432-40
131. Cardozo L, Hessdorfer E, Milani R, et al. SUNRISE Study Group. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: Results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008;102:1120-7
132. Zinner NR, Dmochowski RR, Staskin DR, et al. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn 2011;30:1214-19
133. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
134. Ishizaka N, Noda M, Yokoyama S, et al. Muscarinic acetylcholine receptor subtypes in the human iris. Brain Res 1998;787:344-7
135. Cardozo L, Hessdorfer E, Milani R, et al. SUNRISE Study Group. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: Results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008;102:1120-7
136. Diokno AC, Appell RA, Sand PK, et al. OPERA Study Group. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial. Mayo Clin Proc 2003;78:687-95
137. Hofner K, Oelke M, Machtens S, Grünewald V. Trospium chloride-an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urol 2001;19:336-43
138. Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol 2011;72:186-96
139. Olshansky B, Ebinger U, Brum J, et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: A randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. J Cardiovasc Pharmacol Ther 2008;13:241-51
140. Malhotra B, Wood N, Sachse R, Gandelman K. Thorough QT study of the effect of fesoterodine on cardiac repolarization. Int J Clin Pharmacol Ther 2010;48:309-18
141. Abrams P, Cardozo L, Chapple C, et al. 1032 Study Group. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2006;13:692-8
142. Michel MC,Wetterauer U, Vogel M, De la Rosette JJ. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: A 12-week, open-label, post-marketing surveillance study. Drug Saf 2008;31:505-14
143. Pfizer Detrol- (tolterodine tartrate tablets) US prescribing information March, 2008. Available from: Http://media.pfizer.com/files/products/uspi-detrol. pdf [Last accessed 14 August 2010]
144. Breuel HP, Mürtz G, Bondy S, et al. Safety and tolerance of trospium chloride in the high dose range. Arzneimittelforschung 1993;43:461-4
145. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12
146. Drici MD, Cle'ment N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001;24:575-85
147. Armstrong RB, Dmochowski RR, Sand PK, Macdiarmid S. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: Combined results from two phase 4 controlled clinical trials. Int Urol Nephrol 2007;39:1069-77
148. Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005;45:1038-47
149. Malhotra BK, Glue P, Sweeney K, et al. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007;81:377-85
150. Hussain RM, Hartigan-Go K, Thomas SH, Ford GA. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996;41:73-5
151. Guay DR. Trospium chloride: An update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Clin Risk Manag 2005;1:157-67
152. Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients -a double-blind, placebo-controlled clinical study. Eur Urol 2000;37:702-8
153. Astellas Pharma US VESIcare- (solifenacin succinate) US prescribing information. 2010. Available from: Http://www.astellas.us/docs/vesicare.pdf [Last accessed 7 July 2012]
154. Asajima H, Sekiguchi Y, Matsushima S, et al. QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman. Br J Clin Pharmacol 2008;66:896-7
155. Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005;45:1038-47
156. Donath F, Braeter M, Feustel C. The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients. Int J Clin Pharmacol Ther 2011;49:353-65
157. Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: Central nervous system effects. CNS Neurosci Ther 2012;18:167-74
158. Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc 2011;59:1332-9
159. Pagoria D, O'Connor RC, Guralnick ML. Antimuscarinic drugs: Review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep 2011;12:351-7
160. Swinburn P, Lloyd A, Ali S, et al. Preferences for antimuscarinic therapy for overactive bladder. BJU Int 2011;108:868-73
161. Kraus SR, Ruiz-Cerdá JL, Martire D, et al. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010;76:1350-7
162. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. Am J Geriatr Pharmacother 2006;4:14-24
163. Staskin D, Khullar V, Michel MC, et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourol Urodyn 2011;30:1480-5
164. Sand PK, Goldberg RP, Dmochowski RR, et al. The impact of the overactive bladder syndrome on sexual function: A preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol 2006;195:1730-5
165. Serati M, Salvatore S, Uccella S, et al. Urinary incontinence at orgasm: Relation to detrusor overactivity and treatment efficacy. Eur Urol 2008;54:911-15
166. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999;161:1809-12
167. Stohrer M, Mürtz G, Kramer G, et al. Propiverine Investigator Group. Propiverine compared to oxybutynin in neurogenic detrusor overactivity-results of a randomized, double-blind, multicenter clinical study. Eur Urol 2007;51:235-42
168. Barkin J, Corcos J, Radomski S, et al. UROMAX Study Group. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 2004;26:1026-36
169. Study report 137-219. Double blind, placebo controlled, four- way crossover study to investigate the toleration, safety, pharmacokinetics and pharmacodynamics of single escalating doses of intravenous darifenacin in healthy male volunteers. Novartis; East Hanover (NJ): 2001; Data on file
170. Zobrist RH, Quan D, Thomas HM, et al. Pharmacokinetics and metabolism of transdermal oxybutynin: In vitro and in vivo performance of a novel delivery system. Pharm Res 2003;20:103-9
171. Dmochowski RR, Newman DK, Sand PK, et al. Pharmacokinetics of oxybutynin chloride topical gel: Effects of application site, baths, sunscreen and person-to-person transference. Clin Drug Investig 2011;31(8):559-71
172. May K, Westphal K, Giessmann T, et al. Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: Influence of dosage forms and circadian-time rhythms. J Clin Pharmacol 2008;48:570-9
173. Smulders RA, Krauwinkel WJ, Swart PJ, Huang M. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol 2004;44(9):1023-33
174. Silver N, Sandage B, Sabounjian L, et al. Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. J Clin Pharmacol 2010;50:143-50